Compare Enveric Biosciences Inc (ENVB) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Global X NASDAQ 100 Covered Call ETF trades at $18.15. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | QYLD | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $17.40 | $18.52 |
52-Week Low | $1.28 | $16.46 |
Enterprise Value | $408.82K | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
QYLD trades at $18.05, down 1.74% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF's covered call strategy generates high dividend yields but has historically underperformed the Nasdaq-100's total returns. Recent articles highlight concerns about NAV erosion despite consistent monthly distributions.
The outlook remains mixed - QYLD offers attractive income for yield-seeking investors but faces structural limitations during strong market rallies. Key risks include capped upside potential and competition from lower-fee alternatives. Analyst sentiment is cautious due to long-term underperformance versus the broader index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
